| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Oncology |
Recent Updates
Recently added Catalysts
Estrella Immunopharma, Inc.$0.93
-0.02 (-2.47%)
F 13Pipeline Score Richly Valued Biotech · Clinical
Market Cap
49.92 M
EPS
-0.35
P/E Ratio
-
Value Trade
48.56 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
1.40 M
Operating CF
-6.70 M
Total Assets
3.66 M
Total Liabilities
8.93 M
Equity
-5.27 M
D/E Ratio
12,345
-4.92 %
Week
-36.26 %
1 Month
-3.49 %
3 Month
-27.95 %
6 Month
-88.22 %
5 Year
-88.22 %
All Time
Cash Data
Cash Position
1.93 M
Monthly Burn
2.23 M
Runway
0 mo
Burn Trend
SEC Filing
May 18, 2026
Overview
Volume
49.43 K
52 Week Range
0.78 - 3.15
% held by Insiders
60.61 %
% held by Institutions
12.03 %
Enterprise Value
47.99 M
Total Shares
43.01 M
Short %
0.59 %
Float Shares
15.14 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Estrella Immunopharma, Inc.
30Total events
2Upcoming
7Tier-1 (high impact)
2022 – 2026Coverage
Upcoming catalysts 2
Event history 28
May 5, 2026
◆Oral PresentationPresentation
Estrella Immunopharma to participate in D. Boral Capital Global Conference
Feb 10, 2026
▲Oral PresentationEB103Presentation
Oral presentation of updated STARLIGHT-1 Phase I results at 2026 Tandem Meetings
aggressive B-cell Non-Hodgkin Lymphoma (NHL)source ↗
Feb 9, 2026
▲Oral PresentationEB103Presentation
Oral presentation of updated STARLIGHT-1 Phase I results at 2026 Tandem Meetings
aggressive B-cell Non-Hodgkin Lymphomasource ↗
Feb 4, 2026
◆Late-BreakerEB103Presentation
Late-breaking abstract available online
aggressive B-cell Non-Hodgkin Lymphomasource ↗
Feb 4, 2026
◆Oral PresentationEB103Presentation
Late-breaking oral presentation of Phase 1 STARLIGHT-1 data at 2026 Tandem Meetings
aggressive B-cell Non-Hodgkin Lymphomasource ↗
Feb 2026
◆Oral PresentationEB103Presentation
Late-breaking oral presentation of Phase 1 STARLIGHT-1 data at 2026 Tandem Meetings
aggressive B-cell Non-Hodgkin Lymphomasource ↗
Jan 6, 2026
▼Equity OfferingCorporate
Announced $8.0 million registered direct offering and concurrent private placement
Jan 5, 2026
▼Equity OfferingCorporate
Announced $8.0 million registered direct offering and concurrent private placement
Dec 4, 2025
▲DSMB ReviewEB103Trial
DSMB completed review of Phase I safety data and recommended advancement to Phase II
relapsed/refractory B-cell non-Hodgkin's lymphomasource ↗
Dec 4, 2025
▲Trial InitiationEB103Trial
Phase II expansion phase of STARLIGHT-1 initiated
relapsed/refractory B-cell non-Hodgkin's lymphomasource ↗
Nov 6, 2025
▲Enrollment CompleteEB103Trial
Completed second dose cohort in Phase I portion of STARLIGHT-1 trial
Advanced B-Cell Non-Hodgkin's Lymphomassource ↗
Jun 5, 2025
▲Enrollment UpdateEB103Trial
Activation of second clinical site (Baylor Research Institute) for STARLIGHT-1 trial
relapsed or refractory B-cell non-Hodgkin's lymphomasource ↗
Drug Pipeline Intelligence
F13
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 10%
Micro Cap (rank 821 of 911)
Percentile RankEstrella Immunopharma, Inc. has significant pipeline risk (13/100), with $41M risk-adjusted pipeline value, led by EB103 in B-Cell Non-Hodgkin's Lymphoma (NHL) (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EB103 Monoclonal antibody | B-Cell Non-Hodgkin's Lymphoma (NHL) | Phase 1 | NCT06343311 | 9% | $41M | RECRUITING | 21 | STALLED | D (28) | Dec 31, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
EB103 | B-cell Non-Hodgkin Lymphoma | Phase 1 | 2026-02-10 | Complete Response rate: 100%; n: 9; Duration of Complete Response: 3 to 18 months Read More | Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® Read More | |
EB103 | B-cell Non-Hodgkin Lymphoma | Phase 1 | 2026-02-10 | Complete Response rate: 100%; n: 9; Duration of Complete Response: 3 to 18 months Read More | Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® Read More | |
EB103 | B-cell Non-Hodgkin Lymphoma | Phase 1 | 2026-02-10 | Complete Response rate: 100%; n: 9; Duration of Complete Response: 3 to 18 months Read More | Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ESLA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ESLA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ESLA▼ -8.1%on this news
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
Estrella Immunopharma is set to participate in the D. Boral Capital Global Conference. Details regarding the conference agenda or specific topics of discussion have not been provided. The participation indicates the company's ongoing engagement with investors and stakeholders in the biopharma sector.
Read more →ESLAEstrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
Estrella Immunopharma, Inc. has received initiating coverage from Zacks Small-Cap Research, which has assigned a valuation of $12.00 per share. This coverage emphasizes the company's focus on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies aimed at treating cancer and autoimmune diseases. The report reflects a positive outlook for the company's future.
Read more →ESLAEstrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Estrella Immunopharma presented encouraging results for EB103 at the 2026 Tandem Meetings, showcasing a 100% Complete Response rate in high-risk B-cell Non-Hodgkin Lymphoma patients. The STARLIGHT-1 Phase I study reported no serious adverse events, highlighting EB103's safety and potential as a transformative therapy. The findings suggest significant promise for broader patient populations.
Read more →ESLA▼ -11.1%on this news· ran to +22% by day 3shared move
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Estrella Immunopharma announced that its STARLIGHT-1 Phase 1 study results for EB103 will be presented at the 2026 ASTCT & CIBMTR Tandem Meetings. This study focuses on a novel T-cell therapy targeting CD19 in patients with aggressive B-cell Non-Hodgkin Lymphoma. The late-breaking abstract will be available on February 4, 2026.
Read more →ESLAEstrella Immunopharma Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules EMERYVILLE, CA., JANUARY 5, 2026 - Estrella Immunopharma, Inc. (NASDAQ: ESL
Estrella Immunopharma, Inc. announced an $8 million registered direct offering and concurrent private placement, intended to fund its clinical-stage development of CD19 and CD22-targeted ARTEMIS T-cell therapies. The direct offering includes securities priced at-the-market under Nasdaq rules. The transactions are expected to close on January 6, 2026, and will assist in general corporate purposes and working capital. Aegis Capital Corp. is the exclusive placement agent for these offerings.
Read more →ESLAEstrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Estrella Immunopharma, Inc. has announced a registered direct offering and concurrent private placement expected to generate approximately $8.0 million. The transactions involve the sale of common stock and pre-funded warrants to a single institutional investor. The proceeds will be utilized for general corporate purposes and working capital, with the closing anticipated on January 6, 2026.
Read more →ESLA▲ +12.2%on this news· ran to +23% by day 3
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
Estrella Immunopharma has received a positive recommendation from an independent Data Safety Monitoring Board to advance its STARLIGHT-1 trial into Phase II. This decision follows a successful Phase I dose escalation, where EB103 demonstrated a 100% complete response rate in high-risk patients. The Phase II expansion will further assess the safety and efficacy of the therapy in relapsed/refractory B-cell non-Hodgkin's lymphoma.
Read more →ESLA▲ +7.8%on this news
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients EMERYVILLE, Calif.--( BUSINESS WIRE )-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estr
Estrella Immunopharma has announced the successful completion of the second dose cohort in the STARLIGHT-1 Phase I/II clinical trial for EB103, a T-cell therapy targeting B-cell Non-Hodgkin's Lymphomas. The trial reported a 100% complete response rate among evaluable patients, highlighting the effectiveness of EB103. The safety profile observed during the trial is encouraging, particularly for high-risk patients, indicating potential for a wider application of the therapy. A Data and Safety Monitoring Board will review the findings to determine the next steps for the trial's expansion phase.
Read more →ESLA▲ +7.1%on this news
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma Emeryville, California
Estrella Immunopharma has announced the activation of an additional site for its Phase I/II STARLIGHT-1 trial, which evaluates the EB103 therapy for relapsed or refractory B-cell non-Hodgkin's lymphoma. The new site, located at the Baylor Research Institute in Dallas, Texas, will now facilitate patient enrollment. This expansion is seen as a significant step in accelerating the trial's development and enhancing patient accessibility to the T-cell therapy. The study assesses the safety and optimal dosing of EB103, which targets CD19-positive cancer cells.
Read more →ESLA▼ -14%on this newsshared move
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing Emeryville, California
Estrella Immunopharma has announced a private placement equity financing expected to raise about $3.35 million. The proceeds will be utilized for advancing the STARLIGHT-1 clinical trial of their CD19-redirected ARTEMIS T-cell therapy, EB103, aimed at treating relapsed/refractory B-cell non-Hodgkin's lymphoma. The company plans to issue 2,333,334 shares at $1.50 each. The financing reflects investor confidence in Estrella's innovative immunotherapy approach.
Read more →ESLA▲ +5.2%on this newsshared move
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas Emeryville, California
Estrella Immunopharma has announced the dosing of the first patient in the second cohort of its STARLIGHT-1 trial for EB103, a CD19-redirected T-cell therapy aimed at treating Advanced B-Cell Non-Hodgkin's Lymphomas. This phase of the trial comes after favorable safety data from the initial cohort, which showed no dose-limiting toxicities or serious adverse events. The trial's progress is seen as a significant milestone in Estrella's goal to offer new treatment options for patients, particularly those typically excluded from traditional CAR-T therapies.
Read more →ESLAEstrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort Emeryville, California
Estrella Immunopharma has successfully completed the first dose cohort in its STARLIGHT-1 Phase I/II clinical trial, focusing on EB103 T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The Data and Safety Monitoring Board approved the next higher dose cohort based on favorable safety and efficacy data, which shows no serious adverse events reported. Preliminary results indicate a tumor response in all treated patients at the one-month mark. This advancement highlights the potential of EB103 as a promising therapeutic option in oncology.
Read more →ESLAEstrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
Estrella Immunopharma has appointed Hong Zhang as Chairperson and Board Member, increasing its board from five to six directors. This strategic move follows the dosing of the first patient in the Phase I/II clinical trial for EB103, an innovative T-cell therapy targeting B-cell Non-Hodgkin's Lymphoma. Ms. Zhang brings over 25 years of financial and corporate strategy experience, aiming to strengthen Estrella's mission of developing advanced therapies. CEO Cheng Liu expressed confidence in Zhang's contributions towards the company’s growth and advancement of its therapeutic pipeline.
Read more →ESLAEstrella Immunopharma Doses First Patient in Phase I/II Trial of Anti-CD19 ARTEMIS T-cells in Advanced B-cell Non-Hodgkin's Lymphomas (STARLIGHT-1)
Estrella Immunopharma announced the dosing of the first patient in its Phase I/II clinical trial for EB103, an autologous T-cell therapy aimed at treating relapsed/refractory B-cell Non-Hodgkin's Lymphomas. The trial, named STARLIGHT-1, will evaluate the safety and effectiveness of the therapy, which employs ARTEMIS technology. Experts highlight its potential to provide a safer treatment option compared to traditional CAR-T therapies, particularly for high-risk patients. This milestone marks a significant step in developing advanced treatment options for patients with limited existing alternatives.
Read more →ESLA▲ +10.3%on this news
Developing CD19 - Redirected ARTEMIS T - Cell Therapy for Cancers and Autoimmune Diseases
Estrella Immunopharma is developing a novel CD19-targeted ARTEMIS T-cell therapy designed to treat cancers and autoimmune diseases. Their innovative 'Mark and Kill' strategy combines specially designed oncolytic viruses with T-cell therapy to improve effectiveness while potentially reducing side effects. The company’s lead candidate, EB103, shows promising clinical results and favorable safety. Despite the challenges of existing therapies and competition in the sector, Estrella sees vast opportunities in the autoimmune disease market and plans to advance its clinical programs.
Read more →ESLA▼ -8%on this news
Estrella Immunopharma Announces $1 Million Share Repurchase Authorization Emeryville
Estrella Immunopharma has announced the authorization for a share repurchase of up to $1 million, signaling the company's strong commitment to enhancing shareholder value. This decision reflects confidence in Estrella's strategic direction and the potential of its innovative CD19 and CD22-targeted ARTEMIS T-cell therapies. Management asserts that these initiatives aim to address significant treatment challenges for patients suffering from blood cancers and solid tumors. The timing and execution of the repurchase will depend on future market conditions.
Read more →ESLADescription of the Business Combination On
On September 29, 2023, TradeUP Acquisition Corp. (UPTD) completed its business combination with Estrella Biopharma, Inc. (Estrella), leading to Estrella becoming a wholly-owned subsidiary of UPTD. This transaction is structured as a reverse recapitalization, where Estrella is treated as the acquired company for financial reporting purposes. The unaudited pro forma financials reflect this merger and account for the combined financial metrics post-merger. Despite the optimistic outlook, the pro forma financial information provided is not indicative of future performance and is subject to change as further data is analyzed.
Read more →ESLATradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination New York
TradeUP Acquisition Corp. has announced an extension of its deadline to complete an initial business combination, moving the date from September 19, 2023, to October 19, 2023. This extension is accompanied by a deposit of approximately $37,432.70 into its trust account. Estrella Biopharma, a preclinical-stage biopharmaceutical company, is actively involved in the proposed merger, which remains pending subject to regulatory and shareholder approvals. Shareholders are encouraged to review the forthcoming Proxy Statement/Prospectus for more details on the transaction and associated risks.
Read more →ESLATradeUP Acquisition Corp. Announces Meeting Date for Stockholders to Approve the Business Combination with Estrella Biopharma, Inc. and Liquidation of Investments Held in the Trust Account into Cash New York
TradeUP Acquisition Corp. has scheduled a special meeting for July 31, 2023, for stockholders to vote on a business combination with Estrella Biopharma, a firm focusing on cancer therapeutics. Following SEC approval of the merger's proxy statement, TradeUP will also hold a preliminary meeting to propose extending the timeline for the business combination. Additionally, TradeUP plans to liquidate its Trust Account investments to comply with regulations, which raises liquidity concerns and risks associated with the merger's approval by stockholders.
Read more →ESLATradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination
TradeUP Acquisition Corp. has announced an extension of the deadline for its initial business combination from March 19, 2023, to April 19, 2023. This extension will allow the Company additional time to complete its merger with Estrella Biopharma, a preclinical-stage biopharmaceutical company. To facilitate this extension, TradeUP has deposited a Monthly Extension Fee into its Trust Account. The business combination is still subject to shareholder approval and other closing conditions, which introduces certain risks.
Read more →ESLAEstrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp. Delaware
Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp. Delaware - October 3, 2022 - Estrella Biopharma, Inc. ("Estrella"), a preclinical-stage biopharmaceutical company focusing on cancer therapeutics
Read more →ESLATradeUP Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing
TradeUP Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing September 7, 2021 NEW YORK, September 3, 2021 /PRNewswire/ -- TradeUP Acquisition Corp. (NASDAQ: UPTDU) ("TradeUP Acquisition" or the "Company") announced today that, commenci
Read more →ESLAto this Current Report on Form 8-K. F- 11
Index to Financial Statement Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of July 19, 2021 F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING To the Board of Directors and Stockholders of TradeUP Acquisit
Read more →ESLATradeUP Acquisition Corp. Announces Pricing of $40 Million Initial Public Offering
TradeUP Acquisition Corp. Announces Pricing of $40 Million Initial Public Offering NEW YORK, July 14, 2021 /PRNewswire/ -- TradeUp Acquisition Corp. (NASDAQ: UPTDU, the "Company") announced today the pricing of its initial public offering of 4,000,000 units at a price of $10.0
Read more →Competitive Position
How ESLA ranks across every disease it competes inCompetitive Position is a premium feature
See how ESLA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial